Risperidone Long-Acting Injectable (Lai) Suspension Suppliers & Bulk Manufacturers
Available Forms: Long-acting injectable (LAI) suspension
Available Strengths: 25 mg, 37.5 mg, 50 mg per dose
Reference Brands: Risperdal®(US & EU); EU: Risperidon-ratiopharm®, Rispolept®, Rispen®
Category:
Antipsychotropic Drugs
Risperidone LAI is an atypical antipsychotic that works by antagonizing dopamine D2 and serotonin 5-HT2A receptors, balancing neurotransmission in the brain. It is indicated for the treatment of schizophrenia and bipolar I disorder in adults, providing consistent plasma levels and improving adherence with biweekly or monthly dosing.
Risperidone Long-acting injectable (LAI) suspension is available in Long-acting injectable (LAI) suspension
and strengths such as 25 mg, 37.5 mg, 50 mg per dose.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Risperidone Long-acting injectable (LAI) suspension is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Risperidone Long-acting injectable (LAI) suspension can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Risperidone Long-Acting Injectable (LAI) suspension is approved by the FDA in the United States and the EMA in the European Union for the treatment of schizophrenia and maintenance therapy in bipolar I disorder. It offers an extended-release formulation designed for intramuscular injection every two weeks or monthly, ensuring steady therapeutic levels and improving medication adherence. Regulatory bodies emphasize its importance in reducing relapse rates and hospitalizations. Prescribers must adhere to initiation protocols, especially when transitioning from oral risperidone. To explore additional forms and strengths of risperidone LAI, visit Pharmatradz.com.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing